Avinger, Inc. (AVGR)
NASDAQ: AVGR · IEX Real-Time Price · USD
3.770
+0.110 (3.01%)
At close: Apr 29, 2024, 4:00 PM
3.780
+0.010 (0.27%)
After-hours: Apr 29, 2024, 5:45 PM EDT
Avinger Revenue
In the year 2023, Avinger had annual revenue of $7.65M, a decrease of -7.51%. Revenue in the quarter ending December 31, 2023 was $1.91M, a -4.75% decrease year-over-year.
Revenue (ttm)
$7.65M
Revenue Growth
-7.51%
P/S Ratio
0.84
Revenue / Employee
$112,529
Employees
68
Market Cap
6.42M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.65M | -621.00K | -7.51% |
Dec 31, 2022 | 8.27M | -1.86M | -18.33% |
Dec 31, 2021 | 10.13M | 1.37M | 15.63% |
Dec 31, 2020 | 8.76M | -370.00K | -4.05% |
Dec 31, 2019 | 9.13M | 1.22M | 15.36% |
Dec 31, 2018 | 7.92M | -2.02M | -20.32% |
Dec 31, 2017 | 9.93M | -9.28M | -48.30% |
Dec 31, 2016 | 19.21M | 8.50M | 79.35% |
Dec 31, 2015 | 10.71M | -500.00K | -4.46% |
Dec 31, 2014 | 11.21M | -1.75M | -13.51% |
Dec 31, 2013 | 12.96M | 4.40M | 51.45% |
Dec 31, 2012 | 8.56M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OpGen | 3.07M |
Xenetic Biosciences | 2.54M |
Mangoceuticals | 731.49K |
Azitra | 686.00K |
Assure Holdings | 255.00K |
Titan Pharmaceuticals | 184.00K |
Heart Test Laboratories | 18.60K |
AVGR News
- 5 weeks ago - Avinger Reports Fourth Quarter and Full Year 2023 Results - Accesswire
- 6 weeks ago - Avinger to Announce Full Year 2023 Results on March 20, 2024 - Accesswire
- 7 weeks ago - Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions - PRNewsWire
- 7 weeks ago - Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge - Accesswire
- 6 months ago - Avinger Reports Third Quarter 2023 Results - Accesswire
- 6 months ago - Avinger to Announce Third Quarter 2023 Results on October 26 - Accesswire
- 7 months ago - Avinger Raises $5.3 Million via At-The-Market Facility - Accesswire
- 8 months ago - Avinger stock rockets off a record low after launch of vascular disease treatment system - Market Watch